Pangea Biomed is a cancer treatment technology service provider that aims to bring effective precision oncology to cancer patients, improve oncology drug development, and enable oncologists to successfully treat patients. Recently, Pangea Biomed announced that it has received an additional investment of $5 million, led by angel investor Danny Tocatly and existing investor NFX, which will be used to expand Pangea Biomed’s US operations, promote commercial partnerships and expand product offerings.
This article is transferred from: https://www.itjuzi.com/investevent/13731696
This site is only for collection, and the copyright belongs to the original author.